Crucell Announces PER.C6 and AdVac Technology License Agreement with Wyeth Pharmaceuticals
Crucell N.V. announced that it has entered into a co-exclusive PER.C6® and Advac® technology license agreement with Wyeth Pharmaceuticals, a division of Wyeth.
Under the terms of the agreement, Crucell will receive an upfront payment, milestone payments, annual maintenance fees, and royalties on net product sales. Other financial details were not disclosed.
Crucell's AdVac® technology is a recombinant vector technology used to develop novel adenoviral-based products. PER.C6® technology is based on a human cell line developed for the large-scale manufacture of biological products including vaccines.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.